- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07563283
Singing Intervention for Chronic Obstructive Pulmonary Disease (COPD) (EMPOWER)
Why is this study being done? Chronic Obstructive Pulmonary Disease (COPD) causes airflow blockage creating breathing issues, distress, and lower well-being. COPD also causes hyperinflation of the lungs. The investigators are doing the study to learn more about improving lung function for patients with COPD by using voice-based experiences.
What is being tested in this study? If singing/vocalizing can improve lung function.
How long will I be in the study? The study will last 4 weeks and involve 2 in-person visits to KUMC with virtual vocal sessions two times a week over Zoom.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Study Significance: This study is intended to show if air trapping in functional small airways disease (fSAD) in COPD patients is reduced by a targeted music-based singing intervention.
Air trapping in fSAD in COPD is associated with the experience of breathlessness or dyspnea, which is a primary source of patient distress. Air trapping may be mitigated by activities that support slow, controlled, and more complete exhalation. Because singing requires sustained delivery of consistent air pressure for sound production, training in this activity aims to strengthen respiratory musculature to improve airflow control and increase efficient use of each breath. The investigators believe that singing training will be beneficial in strengthening the respiratory musculature and emptying the lungs, possibly reducing the amount of trapped air.
A major gap exists in understanding whether singing is effective for improving lung function in COPD. Previous interventions based in group singing have been focused on improving social and emotional outcomes, but they do not specifically address the potential physiological benefits of singing as described above. The investigators aim to show specific targeted manipulation of music elements within tailored vocalization activities can successfully improve lung function and reduce dyspnea in patients with COPD, while preserving social and emotional benefits of other more generalized singing interventions. The investigators are focusing on air trapping due to small airways disease as a key symptom that leads to patient experience of dyspnea.(13, 14) Other aspects of COPD pathology and symptoms may be improved by the singing intervention, including a sense of hope through a sense of agency in their own psychological health.
The goal of the pilot study is to determine the feasibility of providing a music-based intervention targeting the issue of air trapping, improve functional small airways disease, and improve other symptoms of COPD and further define the details of the intervention.
This study will determine participant acceptability of a newly developed music-based intervention hoped to be beneficial for people with COPD. If successful, our proposed singing intervention will improve lung function health through reduced air trapping due to hyperinflation, improve patient experience of dyspnea and foster positive psychological health.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Kansas
-
Kansas City, Kansas, Verenigde Staten, 66160
- University of Kansas Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Participants 18 years of age or older
- Diagnosis of COPD
- Airflow obstruction and resting hyperinflation of the lung
- Able to hear within normal range with correction if needed
Exclusion Criteria:
- Pregnancy will be excluded for CT imaging safety and radiation safety
- Alpha-1 antitrypsin
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 4-week singing intervention
Individual virtual singing sessions with a board-certified music therapist designed to target complete exhalation and reduce air trapping
|
Using the Therapeutic Function of Music Plan, this individually tailored music therapy used singing and vocal exercises, guided by a board-certified music therapist, to aid in complete exhalation and reduce air trapping that occurs in chronic obstructive pulmonary disease (COPD).
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Quantitative Computed Tomography (qCT) Air Trapping
Tijdsspanne: Change from baseline after four weeks of the EMPOWER intervention
|
Functional Small Airways Disease Percent (range 0-100), indicating non-emphysematous air trapping percentage (fSAD) as lung volume percent of low attenuation areas below a radiodensity of -856 Hounsfield units (HU) on expiratory computed tomography (CT) and above -950HU on inspiratory CT.
Higher values indicate greater air trapping and worse lung function.
|
Change from baseline after four weeks of the EMPOWER intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Forced Expiratory Volume in 1 second (FEV1)
Tijdsspanne: Change from baseline after four weeks of the EMPOWER intervention
|
FEV1 measures the maximum volume of air (in Liters) forcefully exhaled in the first second of a coached spirometric assessment or pulmonary function test (PFT).
Lower FEV1 indicates worse lung function and obstructive defect in the lungs.
|
Change from baseline after four weeks of the EMPOWER intervention
|
|
Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT)
Tijdsspanne: Change from baseline after four weeks of the EMPOWER intervention
|
Patient reported symptoms of COPD.
The CAT scale contains eight patient-completed questions to assess and monitor COPD symptoms, including the impact on daily life, cough, phlegm, breathlessness, sleep, confidence, and energy.
Scores range from 0-5 on each question for a total scale range of 0-40, with higher scores indicating worse respiratory symptoms.
|
Change from baseline after four weeks of the EMPOWER intervention
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Rebecca J Lepping, PhD, University of Kansas Medical Center
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- STUDY00160422
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .